Hiroyuki Suzuki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hiroyuki Suzuki has a total of 446 co-authors. Here are the top co-authors by number of shared publications:
- Satoshi Muto
Department of Chest Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan
14 shared publications Naoyuki Okabe
Department of Chest Surgery, Fukushima Medical University, Fukushima, Japan
13 shared publicationsTakumi Yamaura
Department of Chest Surgery, Takeda General Hospital, Fukushima, Japan
12 shared publicationsTakeo Hasegawa
Department of Chest Surgery, Fukushima Medical University, Fukushima, Japan
11 shared publicationsYutaka Shio
Department of Chest Surgery Fukushima Medical University Fukushima Japan
11 shared publicationsMitsunori Higuchi
Department of Thoracic Surgery, Aizu Medical Center Fukushima Medical University Aizuwakamatsu Fukushima Japan
10 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Efficacy and Safety of Necitumumab and Pembrolizumab Combination Therapy in Advanced Non–Small Cell Lung Cancer with ≥50% PD-L1 Expression: A Nonrandomized Phase II Trial
Figure S1 from Efficacy and Safety of Necitumumab and Pembrolizumab Combination Therapy in Advanced Non–Small Cell Lung Cancer with ≥50% PD-L1 Expression: A Nonrandomized Phase II Trial
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Efficacy and Safety of Necitumumab and Pembrolizumab Combination Therapy in Advanced Non–Small Cell Lung Cancer with ≥50% PD-L1 Expression: A Nonrandomized Phase II Trial
Figure S1 from Efficacy and Safety of Necitumumab and Pembrolizumab Combination Therapy in Advanced Non–Small Cell Lung Cancer with ≥50% PD-L1 Expression: A Nonrandomized Phase II Trial
- Open Access
- 30 September 2026
- Published by Wiley in Respirology Case Reports
- Vol. 14 (10) , e70763
Long‐Term Survival Following Nivolumab Treatment in Pulmonary Tumour Thrombotic Microangiopathy Associated With Cancer of Unknown Primary: A Case Report
Pulmonary tumour thrombotic microangiopathy (PTTM) is a rare but frequently fatal condition characterized by rapidly progressive pulmonary hypertension and right heart failure caused by tumour microemboli in the pulmonary vasculature. We report the case of a 64‐year‐old man who presented with rapidly progressive respiratory failure. Chest computed tomography demonstrated centrilobular nodules and a tree‐in‐bud (TIB) pattern. Pulmonary perfusion scintigraphy and transthoracic echocardiography suggested pulmonary hypertension with multiple peripheral perfusion defects, raising strong clinical suspicion for PTTM. Transbronchial lung biopsy (TBLB) revealed TTF‐1–positive adenocarcinoma, although the primary tumour site remained undetermined. Based on these findings, clinically suspected PTTM was diagnosed and nivolumab monotherapy was promptly initiated as systemic treatment for the underlying malignancy. Despite transient severe deterioration, the patient's respiratory function improved markedly, and he has remained progression‐free for more than 3 years. This case highlights the importance of early clinical recognition of PTTM and prompt initiation of appropriate systemic therapy, even before definitive identification of the primary tumour when clinically warranted.
- 30 September 2026
- Published by Wiley in Respirology Case Reports
- Vol. 14 (10) , e70763
Open AccessLong‐Term Survival Following Nivolumab Treatment in Pulmonary Tumour Thrombotic Microangiopathy Associated With Cancer of Unknown Primary: A Case Report
Pulmonary tumour thrombotic microangiopathy (PTTM) is a rare but frequently fatal condition characterized by rapidly progressive pulmonary hypertension and right heart failure caused by tumour microemboli in the pulmonary vasculature. We report the case of a 64‐year‐old man who presented with rapidly progressive respiratory failure. Chest computed tomography demonstrated centrilobular nodules and a tree‐in‐bud (TIB) pattern. Pulmonary perfusion scintigraphy and transthoracic echocardiography suggested pulmonary hypertension with multiple peripheral perfusion defects, raising strong clinical suspicion for PTTM. Transbronchial lung biopsy (TBLB) revealed TTF‐1–positive adenocarcinoma, although the primary tumour site remained undetermined. Based on these findings, clinically suspected PTTM was diagnosed and nivolumab monotherapy was promptly initiated as systemic treatment for the underlying malignancy. Despite transient severe deterioration, the patient's respiratory function improved markedly, and he has remained progression‐free for more than 3 years. This case highlights the importance of early clinical recognition of PTTM and prompt initiation of appropriate systemic therapy, even before definitive identification of the primary tumour when clinically warranted.
- 27 July 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (20) , 4571-4579
Efficacy and Safety of Necitumumab and Pembrolizumab Combination Therapy in Advanced Non–Small Cell Lung Cancer with ≥50% PD-L1 Expression: A Nonrandomized Phase II Trial
Purpose: This study investigated the efficacy and safety of pembrolizumab and necitumumab as first-line therapy for patients with advanced non–small cell lung cancer (NSCLC) who had ≥50% programmed death-ligand 1 (PD-L1) expression. Patients and Methods: This nonrandomized, multicenter, open-label, single-arm phase II trial included patients with previously untreated advanced NSCLC who had a PD-L1 tumor proportion score of ≥50%. Patients received pembrolizumab and necitumumab every 3 weeks for up to 35 cycles. The primary endpoint was the investigator-assessed objective response rate (ORR). The secondary endpoints included progression-free survival (PFS), overall survival (OS), and safety. Results: The sample comprised 50 patients (38 men, 12 women; median age, 72 years; range, 51–90 years). The ORR was 76% (95% confidence interval, 61.9–86.9; P < 0.0001), with complete and partial response rates of 2% and 74%, respectively. Moreover, 10% and 8% of the patients had stable and progressive disease, respectively, whereas 6% could not be evaluated. The median PFS was 15.7 months, whereas the median OS was not reached at the time of analysis. The most common treatment-related adverse events were rash (64%) and hypomagnesemia (60%). Grade 3 interstitial lung disease occurred in five patients (10%), and grade 5 cardiac arrest occurred in one patient (2%). Conclusions: The pembrolizumab and necitumumab combination exhibited a promising ORR of 76% with a manageable safety profile in patients with NSCLC who had high PD-L1 expression. These findings highlight the need for further research on this regimen for patients with advanced NSCLC who have high PD-L1 expression.
- 27 July 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (20) , 4571-4579
Efficacy and Safety of Necitumumab and Pembrolizumab Combination Therapy in Advanced Non–Small Cell Lung Cancer with ≥50% PD-L1 Expression: A Nonrandomized Phase II Trial
Purpose: This study investigated the efficacy and safety of pembrolizumab and necitumumab as first-line therapy for patients with advanced non–small cell lung cancer (NSCLC) who had ≥50% programmed death-ligand 1 (PD-L1) expression. Patients and Methods: This nonrandomized, multicenter, open-label, single-arm phase II trial included patients with previously untreated advanced NSCLC who had a PD-L1 tumor proportion score of ≥50%. Patients received pembrolizumab and necitumumab every 3 weeks for up to 35 cycles. The primary endpoint was the investigator-assessed objective response rate (ORR). The secondary endpoints included progression-free survival (PFS), overall survival (OS), and safety. Results: The sample comprised 50 patients (38 men, 12 women; median age, 72 years; range, 51–90 years). The ORR was 76% (95% confidence interval, 61.9–86.9; P < 0.0001), with complete and partial response rates of 2% and 74%, respectively. Moreover, 10% and 8% of the patients had stable and progressive disease, respectively, whereas 6% could not be evaluated. The median PFS was 15.7 months, whereas the median OS was not reached at the time of analysis. The most common treatment-related adverse events were rash (64%) and hypomagnesemia (60%). Grade 3 interstitial lung disease occurred in five patients (10%), and grade 5 cardiac arrest occurred in one patient (2%). Conclusions: The pembrolizumab and necitumumab combination exhibited a promising ORR of 76% with a manageable safety profile in patients with NSCLC who had high PD-L1 expression. These findings highlight the need for further research on this regimen for patients with advanced NSCLC who have high PD-L1 expression.
- 1 October 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (2) , 231-249
Stratifying lung adenocarcinoma risk with multi-ancestry polygenic risk scores in East Asian never-smokers
Background: Lung adenocarcinoma in never-smokers is a major public health burden, especially among East Asian women. Polygenic risk scores (PRSs) are promising for risk stratification but are primarily developed in European-ancestry populations. We aimed to develop and validate single- and multi-ancestry PRSs for East Asian never-smokers to improve lung adenocarcinoma risk prediction. Methods: PRSs were developed using genome-wide association study summary statistics from East Asian (8002 cases; 20 782 controls) and European (2058 cases; 5575 controls) populations. Single-ancestry models included a PRS with 25 single nucleotide variants (PRS-25), PRS clumping and thresholding (CT), and LDpred2; multi-ancestry models included LDpred2 plus European PRS-128, PRS-CSx, and clumping and thresholding, super learning, empirical Bayes (CT-SLEB). Performance was evaluated in independent East Asian data from the Female Lung Cancer Consortium and externally validated in the Nanjing Lung Cancer Cohort. We assessed predictive accuracy via area under the curve operating procedure (AUC), with 10-year and (ages 30-80 years) absolute risks estimates. Results: The best multi-ancestry PRS, using East Asian and European data via CT-SLEB, outperformed the best East Asian-only (LDpred2; AUC = 0.629, 95% confidence interval [CI] = 0.618 to 0.641), achieving an AUC of 0.640 (95% CI = 0.629 to 0.653) and odds ratio of 1.71 (95% CI = 1.61 to 1.82) per standard deviation increase. Nanjing Lung Cancer Cohort validation confirmed robust performance (AUC = 0.649, 95% CI = 0.623 to 0.676). The top 20% PRS group had a 3.92-fold higher lung adenocarcinoma risk than the bottom 20%. Further, the top 5% PRS group reached a 6.69% lifetime absolute risk. Notably, this group reached the average population 10-year lung adenocarcinoma risk at age 50 years (0.42%) by age 41 years, 9 years earlier. Conclusions: Multi-ancestry PRS approaches enhance lung adenocarcinoma risk stratification in East Asian never-smokers, with consistent external validation, suggesting future clinical utility.
- 1 October 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (2) , 231-249
Stratifying lung adenocarcinoma risk with multi-ancestry polygenic risk scores in East Asian never-smokers
Background: Lung adenocarcinoma in never-smokers is a major public health burden, especially among East Asian women. Polygenic risk scores (PRSs) are promising for risk stratification but are primarily developed in European-ancestry populations. We aimed to develop and validate single- and multi-ancestry PRSs for East Asian never-smokers to improve lung adenocarcinoma risk prediction. Methods: PRSs were developed using genome-wide association study summary statistics from East Asian (8002 cases; 20 782 controls) and European (2058 cases; 5575 controls) populations. Single-ancestry models included a PRS with 25 single nucleotide variants (PRS-25), PRS clumping and thresholding (CT), and LDpred2; multi-ancestry models included LDpred2 plus European PRS-128, PRS-CSx, and clumping and thresholding, super learning, empirical Bayes (CT-SLEB). Performance was evaluated in independent East Asian data from the Female Lung Cancer Consortium and externally validated in the Nanjing Lung Cancer Cohort. We assessed predictive accuracy via area under the curve operating procedure (AUC), with 10-year and (ages 30-80 years) absolute risks estimates. Results: The best multi-ancestry PRS, using East Asian and European data via CT-SLEB, outperformed the best East Asian-only (LDpred2; AUC = 0.629, 95% confidence interval [CI] = 0.618 to 0.641), achieving an AUC of 0.640 (95% CI = 0.629 to 0.653) and odds ratio of 1.71 (95% CI = 1.61 to 1.82) per standard deviation increase. Nanjing Lung Cancer Cohort validation confirmed robust performance (AUC = 0.649, 95% CI = 0.623 to 0.676). The top 20% PRS group had a 3.92-fold higher lung adenocarcinoma risk than the bottom 20%. Further, the top 5% PRS group reached a 6.69% lifetime absolute risk. Notably, this group reached the average population 10-year lung adenocarcinoma risk at age 50 years (0.42%) by age 41 years, 9 years earlier. Conclusions: Multi-ancestry PRS approaches enhance lung adenocarcinoma risk stratification in East Asian never-smokers, with consistent external validation, suggesting future clinical utility.
- 23 September 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 74 (3) , 295-310
Targeting colony-stimulating factor-1 receptor attenuates the development of pulmonary arterial hypertension through C-C motif chemokine ligand 2
Background: Pulmonary arterial hypertension (PAH) is a progressive disease characterized by elevated pulmonary arterial pressure and right ventricular failure. The perivascular macrophages in the lungs play a crucial role in the development of PAH. Here, we tested the hypothesis that colony-stimulating factor 1 receptor (CSF1R), essential for macrophage proliferation and polarization, contributed to the progression of PAH, and targeting CSF1R could offer a potential therapeutic strategy. Methods and results: In the lungs of patients with PAH, we found that the number of perivascular CSF1R-positive macrophages and M2 macrophages significantly increased. In the experimental sugen/hypoxia-induced PAH model, knockdown of CSF1R in the lungs decreased right ventricular systolic pressure and the number of perivascular macrophages. Pharmacological inhibition with a CSF1R inhibitor, pexidartinib, and anti-CSF1R neutralizing antibody blocked perivascular macrophage accumulation and improved the severity of pulmonary hypertension in the murine PAH models. Mechanistically, C-C motif chemokine ligand 2 (CCL2) produced by M2 macrophages was identified as a key driver for pulmonary artery smooth muscle cell proliferation, leading to pulmonary arterial remodeling. Activation of CSF1R and c-Jun N terminal kinase (JNK) transcriptionally regulated Ccl2 expressions in macrophages. Conclusion: Our study suggests that CSF1R and M2 macrophages have critical roles in the progression of PAH through CCL2.
- 23 September 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 74 (3) , 295-310
Targeting colony-stimulating factor-1 receptor attenuates the development of pulmonary arterial hypertension through C-C motif chemokine ligand 2
Background: Pulmonary arterial hypertension (PAH) is a progressive disease characterized by elevated pulmonary arterial pressure and right ventricular failure. The perivascular macrophages in the lungs play a crucial role in the development of PAH. Here, we tested the hypothesis that colony-stimulating factor 1 receptor (CSF1R), essential for macrophage proliferation and polarization, contributed to the progression of PAH, and targeting CSF1R could offer a potential therapeutic strategy. Methods and results: In the lungs of patients with PAH, we found that the number of perivascular CSF1R-positive macrophages and M2 macrophages significantly increased. In the experimental sugen/hypoxia-induced PAH model, knockdown of CSF1R in the lungs decreased right ventricular systolic pressure and the number of perivascular macrophages. Pharmacological inhibition with a CSF1R inhibitor, pexidartinib, and anti-CSF1R neutralizing antibody blocked perivascular macrophage accumulation and improved the severity of pulmonary hypertension in the murine PAH models. Mechanistically, C-C motif chemokine ligand 2 (CCL2) produced by M2 macrophages was identified as a key driver for pulmonary artery smooth muscle cell proliferation, leading to pulmonary arterial remodeling. Activation of CSF1R and c-Jun N terminal kinase (JNK) transcriptionally regulated Ccl2 expressions in macrophages. Conclusion: Our study suggests that CSF1R and M2 macrophages have critical roles in the progression of PAH through CCL2.
- Open Access
- 22 November 2023
- Published by Springer Nature in General Thoracic and Cardiovascular Surgery Cases
- Vol. 2 (1) , 1-4
Successful pericardial repair and coverage for late pacemaker lead-related atrial perforation and pneumothorax: a case report
Background: Various complications of permanent pacemaker implantation have been reported. However, late pacemaker lead-related myocardial perforation rarely occurs. Conservative treatment is generally selected, if possible, but open heart surgery or catheter lead removal should be considered in symptomatic patients. We herein describe a patient who was successfully treated by pericardial repair and coverage for late pacemaker lead-related atrial perforation and pneumothorax. Case presentation: A woman in her 80s who had undergone permanent pacemaker implantation 2 years previously visited our hospital because of dyspnea. She had also been treated for right pneumothorax 1 year previously. A chest radiograph and computed tomography scan showed right pneumothorax and pericardial emphysema with no effusion. Because similar findings had been obtained at the previous onset of pneumothorax, we suspected delayed myocardial perforation and lung injury due to the screw-in lead in the right atrium. No myocardial bleeding, cardiac tamponade, or pacing failure was present. The cardiovascular surgeon judged that open-heart lead extraction would be difficult because of the patient’s poor performance status; therefore, thoracoscopic pericardial repair with an expanded polytetrafluoroethylene sheet and coverage with anterior mediastinal adipose tissue was attempted to prevent recurrent pneumothorax. The patient was successfully treated without lead extraction or open heart surgery. At 1.5 years postoperatively, she had developed no recurrence of pneumothorax or pacing failure. Conclusions: Pericardial repair and coverage can be an effective strategy for pacemaker lead-related pneumothorax without pacing failure or bleeding.
- 22 November 2023
- Published by Springer Nature in General Thoracic and Cardiovascular Surgery Cases
- Vol. 2 (1) , 1-4
Open AccessSuccessful pericardial repair and coverage for late pacemaker lead-related atrial perforation and pneumothorax: a case report
Background: Various complications of permanent pacemaker implantation have been reported. However, late pacemaker lead-related myocardial perforation rarely occurs. Conservative treatment is generally selected, if possible, but open heart surgery or catheter lead removal should be considered in symptomatic patients. We herein describe a patient who was successfully treated by pericardial repair and coverage for late pacemaker lead-related atrial perforation and pneumothorax. Case presentation: A woman in her 80s who had undergone permanent pacemaker implantation 2 years previously visited our hospital because of dyspnea. She had also been treated for right pneumothorax 1 year previously. A chest radiograph and computed tomography scan showed right pneumothorax and pericardial emphysema with no effusion. Because similar findings had been obtained at the previous onset of pneumothorax, we suspected delayed myocardial perforation and lung injury due to the screw-in lead in the right atrium. No myocardial bleeding, cardiac tamponade, or pacing failure was present. The cardiovascular surgeon judged that open-heart lead extraction would be difficult because of the patient’s poor performance status; therefore, thoracoscopic pericardial repair with an expanded polytetrafluoroethylene sheet and coverage with anterior mediastinal adipose tissue was attempted to prevent recurrent pneumothorax. The patient was successfully treated without lead extraction or open heart surgery. At 1.5 years postoperatively, she had developed no recurrence of pneumothorax or pacing failure. Conclusions: Pericardial repair and coverage can be an effective strategy for pacemaker lead-related pneumothorax without pacing failure or bleeding.
- Open Access
- 20 July 2023
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 18 (1) , 1-8
Salvage surgery for advanced non-small cell lung cancer following previous immunotherapy: a retrospective study
Background: The development of systemic chemotherapy including immune checkpoint inhibitors (ICIs) has provided patients with unresectable advanced non-small cell lung cancer (NSCLC) an opportunity to undergo surgical intervention after initial treatment. However, no consensus regarding the indication for salvage surgery in these patients has been reached. Methods: We conducted a retrospective study of patients who underwent salvage surgery for advanced NSCLC (cStage IIIA–IVB) after treatment with ICIs from January 2018 to December 2022 at Aizu Medical Center and Fukushima Medical University Hospital. We evaluated the patients’ clinical data, calculated disease-free survival (DFS) and overall survival (OS), and assessed the survival benefit using the Kaplan–Meier method. Results: Thirteen patients underwent salvage surgery after immunotherapy. All patients achieved downstaging after initial chemotherapy. Eleven patients underwent lobectomy, and one patient underwent extirpation of intra-abdominal lymph nodes. The mean surgery time and intraoperative blood loss were 242.2 min and 415.1 g, respectively. The mean drainage period was 4.2 days (range, 2–9 days). Grade ≥ 3 postoperative complications were confirmed in three patients. The 2-year DFS rate was 71.2%, and the 2-year OS rate was 76.2%. A pathological complete response compatible with ypStage 0 was achieved in four (30.8%) patients. Patients with ypStage 0 and I achieved significantly better OS than those with ypStage ≥ II (p = 0.044), and patients without severe complications achieved significantly better DFS and OS than those with severe complications (p = 0.001 and p < 0.001, respectively). Conclusions: Salvage surgery after chemotherapy including ICIs is a feasible and effective treatment option for patients with advanced NSCLC, especially those who acquire downstaging to pathological stage 0 or I. However, severe perioperative complications might affect patient survival. A prospective study is urgently needed to evaluate the efficacy of salvage surgery.
- 20 July 2023
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 18 (1) , 1-8
Open AccessSalvage surgery for advanced non-small cell lung cancer following previous immunotherapy: a retrospective study
Background: The development of systemic chemotherapy including immune checkpoint inhibitors (ICIs) has provided patients with unresectable advanced non-small cell lung cancer (NSCLC) an opportunity to undergo surgical intervention after initial treatment. However, no consensus regarding the indication for salvage surgery in these patients has been reached. Methods: We conducted a retrospective study of patients who underwent salvage surgery for advanced NSCLC (cStage IIIA–IVB) after treatment with ICIs from January 2018 to December 2022 at Aizu Medical Center and Fukushima Medical University Hospital. We evaluated the patients’ clinical data, calculated disease-free survival (DFS) and overall survival (OS), and assessed the survival benefit using the Kaplan–Meier method. Results: Thirteen patients underwent salvage surgery after immunotherapy. All patients achieved downstaging after initial chemotherapy. Eleven patients underwent lobectomy, and one patient underwent extirpation of intra-abdominal lymph nodes. The mean surgery time and intraoperative blood loss were 242.2 min and 415.1 g, respectively. The mean drainage period was 4.2 days (range, 2–9 days). Grade ≥ 3 postoperative complications were confirmed in three patients. The 2-year DFS rate was 71.2%, and the 2-year OS rate was 76.2%. A pathological complete response compatible with ypStage 0 was achieved in four (30.8%) patients. Patients with ypStage 0 and I achieved significantly better OS than those with ypStage ≥ II (p = 0.044), and patients without severe complications achieved significantly better DFS and OS than those with severe complications (p = 0.001 and p < 0.001, respectively). Conclusions: Salvage surgery after chemotherapy including ICIs is a feasible and effective treatment option for patients with advanced NSCLC, especially those who acquire downstaging to pathological stage 0 or I. However, severe perioperative complications might affect patient survival. A prospective study is urgently needed to evaluate the efficacy of salvage surgery.
- Open Access
- 12 January 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (1) , 190
Wnt/β-Catenin Signaling and Resistance to Immune Checkpoint Inhibitors: From Non-Small-Cell Lung Cancer to Other Cancers
Lung cancer is the leading cause of cancer-related deaths worldwide. The standard of care for advanced non-small-cell lung cancer (NSCLC) without driver-gene mutations is a combination of an anti-PD-1/PD-L1 antibody and chemotherapy, or an anti-PD-1/PD-L1 antibody and an anti-CTLA-4 antibody with or without chemotherapy. Although there were fewer cases of disease progression in the early stages of combination treatment than with anti-PD-1/PD-L1 antibodies alone, only approximately half of the patients had a long-term response. Therefore, it is necessary to elucidate the mechanisms of resistance to immune checkpoint inhibitors. Recent reports of such mechanisms include reduced cancer-cell immunogenicity, loss of major histocompatibility complex, dysfunctional tumor-intrinsic interferon-γ signaling, and oncogenic signaling leading to immunoediting. Among these, the Wnt/β-catenin pathway is a notable potential mechanism of immune escape and resistance to immune checkpoint inhibitors. In this review, we will summarize findings on these resistance mechanisms in NSCLC and other cancers, focusing on Wnt/β-catenin signaling. First, we will review the molecular biology of Wnt/β-catenin signaling, then discuss how it can induce immunoediting and resistance to immune checkpoint inhibitors. We will also describe other various mechanisms of immune-checkpoint-inhibitor resistance. Finally, we will propose therapeutic approaches to overcome these mechanisms.
- 12 January 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (1) , 190
Open AccessWnt/β-Catenin Signaling and Resistance to Immune Checkpoint Inhibitors: From Non-Small-Cell Lung Cancer to Other Cancers
Lung cancer is the leading cause of cancer-related deaths worldwide. The standard of care for advanced non-small-cell lung cancer (NSCLC) without driver-gene mutations is a combination of an anti-PD-1/PD-L1 antibody and chemotherapy, or an anti-PD-1/PD-L1 antibody and an anti-CTLA-4 antibody with or without chemotherapy. Although there were fewer cases of disease progression in the early stages of combination treatment than with anti-PD-1/PD-L1 antibodies alone, only approximately half of the patients had a long-term response. Therefore, it is necessary to elucidate the mechanisms of resistance to immune checkpoint inhibitors. Recent reports of such mechanisms include reduced cancer-cell immunogenicity, loss of major histocompatibility complex, dysfunctional tumor-intrinsic interferon-γ signaling, and oncogenic signaling leading to immunoediting. Among these, the Wnt/β-catenin pathway is a notable potential mechanism of immune escape and resistance to immune checkpoint inhibitors. In this review, we will summarize findings on these resistance mechanisms in NSCLC and other cancers, focusing on Wnt/β-catenin signaling. First, we will review the molecular biology of Wnt/β-catenin signaling, then discuss how it can induce immunoediting and resistance to immune checkpoint inhibitors. We will also describe other various mechanisms of immune-checkpoint-inhibitor resistance. Finally, we will propose therapeutic approaches to overcome these mechanisms.
- Open Access
- 22 September 2022
- Published by Wiley in Thoracic Cancer
- Vol. 13 (21) , 3076-3079
Lung adenocarcinoma coexisting with diffuse idiopathic pulmonary neuroendocrine cell hyperplasia manifesting as multiple pulmonary nodules: A case report
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH), a rare condition, is characterized by pathological proliferation of neuroendocrine cells. Some of them are localized to the airway mucosa, and others locally infiltrate to form tumorlets and nodules. Here, we present a patient with lung adenocarcinoma accompanied by DIPNECH, making the latter difficult to distinguish from multiple pulmonary metastases. The patient, a 72‐year‐old Japanese woman, was diagnosed as having stage IVA lung adenocarcinoma because she had multiple nodules in both lungs. Mutation of epidermal growth factor receptor gene having been found in the primary tumor, treatment with osimertinib was started. This resulted in shrinkage of the primary tumor, but not the multiple pulmonary nodules. To determine whether these lung nodules were indeed lung metastases, we performed right upper lobectomy with lymphadenectomy and wedge resection of the right lower lobe. On pathological examination, the primary tumor was diagnosed as invasive adenocarcinoma, whereas the multiple pulmonary nodules were diagnosed as DIPNECH manifesting as tumorlets. Therefore, the final diagnosis was stage IA1 lung adenocarcinoma accompanied by DINPECH. The patient had no recurrences 1 year after the operation without any additional treatment. This is a rare case of lung adenocarcinoma accompanied by DIPNECH presenting as multiple pulmonary nodules. DIPNECH should be included in the differential diagnosis of multiple pulmonary nodules.
- 22 September 2022
- Published by Wiley in Thoracic Cancer
- Vol. 13 (21) , 3076-3079
Open AccessLung adenocarcinoma coexisting with diffuse idiopathic pulmonary neuroendocrine cell hyperplasia manifesting as multiple pulmonary nodules: A case report
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH), a rare condition, is characterized by pathological proliferation of neuroendocrine cells. Some of them are localized to the airway mucosa, and others locally infiltrate to form tumorlets and nodules. Here, we present a patient with lung adenocarcinoma accompanied by DIPNECH, making the latter difficult to distinguish from multiple pulmonary metastases. The patient, a 72‐year‐old Japanese woman, was diagnosed as having stage IVA lung adenocarcinoma because she had multiple nodules in both lungs. Mutation of epidermal growth factor receptor gene having been found in the primary tumor, treatment with osimertinib was started. This resulted in shrinkage of the primary tumor, but not the multiple pulmonary nodules. To determine whether these lung nodules were indeed lung metastases, we performed right upper lobectomy with lymphadenectomy and wedge resection of the right lower lobe. On pathological examination, the primary tumor was diagnosed as invasive adenocarcinoma, whereas the multiple pulmonary nodules were diagnosed as DIPNECH manifesting as tumorlets. Therefore, the final diagnosis was stage IA1 lung adenocarcinoma accompanied by DINPECH. The patient had no recurrences 1 year after the operation without any additional treatment. This is a rare case of lung adenocarcinoma accompanied by DIPNECH presenting as multiple pulmonary nodules. DIPNECH should be included in the differential diagnosis of multiple pulmonary nodules.